SCHEMBL5406530

SCHEMBL5406530

Cc1cc2c(cc1C)C(C)(C)CC2=C(C#N)C(=O)C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.32
RARG P13631 1/20 0.32
RXRA P19793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406525 1.00 RARB (0.32) RARBRARGRXRA
SCHEMBL5406948 0.92 RARB (0.30) RARBRARGRXRA
SCHEMBL5406952 0.92 RARB (0.30) RARBRARGRXRA
SCHEMBL5403690 0.88 EGFR (0.31)
SCHEMBL5403688 0.88 EGFR (0.31)
SCHEMBL14439938 0.88
SCHEMBL5398488 0.85 RARA (0.31) RARBRARGRXRA
SCHEMBL5398492 0.85 RARA (0.31) RARBRARGRXRA
SCHEMBL5397192 0.84 ALDH1A1 (0.36) RARBRARGRXRA
SCHEMBL14543060 0.84 RARA (0.30) RARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1246303-C Indanylidene compounds THIMRASS KG (DE) 2006-03-22 CN claimed
EP-1466892-A1 Novel indanylidene compounds Symrise GmbH & Co. KG (DE) 2004-10-13 EP claimed
EP-1341752-B1 NOVEL INDANYLIDENE COMPOUNDS SYMRISE GMBH & CO KG (DE) 2004-08-04 EP claimed
CN-1473146-A Novel indanylidene compounds ������������� 2004-02-04 CN claimed
US-20020143203-A1 Novel indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2002-10-03 US claimed
US-20070185057-A1 Novel Indanone Compounds SYMRISE GMBH & CO. KG (DE) 2007-08-09 US disclosed
US-7208142-B2 Indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2007-04-24 US disclosed
CN-1246303-C Indanylidene compounds THIMRASS KG (DE) 2006-03-22 CN disclosed
EP-1466892-A1 Novel indanylidene compounds Symrise GmbH & Co. KG (DE) 2004-10-13 EP disclosed
EP-1341752-B1 NOVEL INDANYLIDENE COMPOUNDS SYMRISE GMBH & CO KG (DE) 2004-08-04 EP disclosed
CN-1473146-A Novel indanylidene compounds ������������� 2004-02-04 CN disclosed
US-20020143203-A1 Novel indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185057-A1 Novel Indanone Compounds CUTA, NISCH, TYR RARB 1465/4885RARG 1708/4885RXRA 2095/4885
US-20020143203-A1 Novel indanylidene compounds CUTA, NISCH, ERCC4 RARB 649/4885RARG 660/4885RXRA 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.